Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wave Life Sciences Ltd. (Nasdaq: WVE) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed through EDGAR. Wave is a clinical-stage biotechnology company incorporated in Singapore with ordinary shares listed on The Nasdaq Global Market, and it uses SEC filings to report material events, financial results, securities offerings, and corporate actions.
Recent WVE SEC filings include multiple Forms 8-K describing public offerings of ordinary shares and pre-funded warrants under an automatically effective shelf registration statement on Form S-3ASR, along with related underwriting agreements and legal opinions. Other 8-K filings furnish press releases covering quarterly financial results, clinical data updates for programs such as WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, and corporate presentations made available to investors.
Wave also files 8-Ks to report shareholder meeting outcomes and compensation-related matters, such as amendments to its equity incentive plan and voting results from its annual general meeting. Many of these filings specify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and indicate when press releases or slide decks are incorporated by reference.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items like new securities offerings, changes to compensation plans, or important clinical and financial announcements referenced in 8-Ks. Users can review filing titles, dates, and summarized content, then open the full SEC documents for detailed analysis of Wave Life Sciences’ regulatory and disclosure history.
RA Capital and affiliates report a larger stake in Wave Life Sciences Ltd., now beneficially owning 34,225,506 ordinary shares, or 17.5% of the company’s outstanding shares. The ownership is reported across RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah.
The amendment details recent open-market purchases by RA Capital Healthcare Fund, including multi-million share buys on March 26, 27, and 30, 2026 at weighted-average prices between $6.06 and $6.50 per share, funded with the fund’s working capital. Certain shares are issuable upon exercise of pre-funded warrants and stock options.
Wave Life Sciences Ltd. reported significant open-market buying by entities associated with RA Capital. RA Capital Healthcare Fund LP, advised by RA Capital Management, L.P., purchased a total of 8,772,496 ordinary shares in open-market transactions between March 26 and March 30, 2026 at prices around $6.06–$6.50 per share. Following these purchases, the Fund’s indirect holdings reached 26,975,505 ordinary shares, with an additional 28,815 shares linked to previously reported RSU awards held by Dr. Peter Kolchinsky for the benefit of the Fund. The Adviser, its general partner, the Fund, Dr. Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Wave Life Sciences Ltd. reported that entities associated with director Ken Takanashi converted 3,901,348 Series A preferred shares into the same number of ordinary shares on a one-for-one basis. This was a non-cash derivative conversion, not an open-market purchase or sale.
After the conversion, those entities collectively held 9,606,408 ordinary shares indirectly, while Takanashi also held 23,943 ordinary shares directly. Footnotes state the shares are held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., and Takanashi disclaims beneficial ownership except to the extent of his pecuniary interest.
Wave Life Sciences reported positive interim Phase 1 data from its INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity. After six months, a single 240 mg dose produced placebo-adjusted reductions in visceral fat of -14%, total fat of -5%, waist circumference of -3%, and body weight of -1%, while lean mass increased by +2%. WVE-007 showed durable, dose-dependent suppression of serum Activin E for at least seven months, supporting the potential for once or twice-yearly dosing, and was generally safe and well tolerated up to 600 mg, with only mild or moderate adverse events.
Wave Life Sciences Ltd. officer Francis Chris reported option exercises and share sales in Wave Life Sciences ordinary shares. On February 26, 2026, he exercised two share options for 17,900 and 15,294 shares at exercise prices of $3.87 and $4.75 per share, respectively, receiving the corresponding ordinary shares. He then sold 17,900 shares at a weighted-average price of $15.094 per share and 15,294 shares at $15.00 per share in open-market transactions. The filing notes these transactions were carried out under a pre-established Rule 10b5‑1 trading plan, and after the reported trades he held 61,867 ordinary shares directly.
Wave Life Sciences Ltd. provides an annual overview of its business, pipeline and risks as a clinical-stage RNA medicines company. The company focuses on obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease, Duchenne muscular dystrophy and Huntington’s disease using its PRISM chemistry platform.
Lead programs include WVE-007 for obesity, WVE-006 for AATD and WVE-008 for PNPLA3 I148M liver disease, alongside WVE-N531 for DMD and WVE-003 for allele-selective Huntington’s disease. As of June 30, 2025, the aggregate market value of non-affiliate shares was $851,013,538, and ordinary shares outstanding were 188,254,954 as of February 19, 2026.
Wave Life Sciences reported much higher cash and a larger loss for 2025 while outlining ambitious RNA programs in obesity, liver and lung disease. Cash and cash equivalents rose to $602.1 million as of December 31, 2025, giving an expected cash runway into Q3 2028.
Full-year 2025 revenue was $42.7 million, down from $108.3 million in 2024, as collaboration revenue declined. Research and development expenses increased to $182.8 million and general and administrative to $75.3 million, driving a net loss of $204.4 million versus a $97.0 million loss in 2024.
The company highlighted WVE-007 for obesity, where a single dose showed fat loss similar to GLP‑1 drugs at three months while preserving lean mass, with data updates and a Phase 2a multidose trial planned in 2026. It also advanced WVE‑006 for alpha‑1 antitrypsin deficiency, achieving total AAT levels above 11 micromolar and dynamic increases during acute phase responses, and plans a 2026 clinical trial application for WVE‑008 in PNPLA3 I148M liver disease.
Wave Life Sciences Ltd. received an updated ownership report from Adage Capital Management, L.P. and principals Robert Atchinson and Phillip Gross. The reporting group states beneficial ownership of 9,786,061 ordinary shares, representing 5.35% of the class as of the event date.
All 9,786,061 shares are reported with shared voting and shared dispositive power, and no shares with sole power. The percentage is based on a total of 182,971,259 ordinary shares outstanding, which combines 167,181,784 shares outstanding as of November 7, 2025 and 15,789,475 shares offered under a December 11, 2025 prospectus. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Wave Life Sciences’ Chief Financial Officer Kyle Moran reported routine equity compensation and a related tax sale. On February 5, 2026, he received 45,625 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 273,750 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly thereafter until February 8, 2030. Following these grants, he held 137,973 ordinary shares and 273,750 options directly. On February 9, 2026, he sold 3,588 ordinary shares at $13.45 per share to cover taxes triggered by RSU vesting under an automatic sale provision, leaving 134,385 ordinary shares owned directly.
Wave Life Sciences Ltd. insider activity: President and CEO Paul Bolno received 165,000 restricted share units on February 5, 2026, bringing his direct holdings to 286,000 ordinary shares. These RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030.
On February 9, 2026, he sold 10,480 ordinary shares at $13.45 each solely to cover taxes from RSU vesting, leaving 275,520 shares owned directly. He also received a stock option for 1,000,000 ordinary shares at a $12.75 exercise price, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030.